buserelin has been researched along with nilutamide in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (73.08) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 4 (15.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campus, G; D'Atri, M; De Lisa, A; Migliari, R; Scarpa, RM; Serra, A; Usai, E; Zucca, I | 1 |
| Denis, L | 1 |
| Billebaud, T; Costa, P; Dahan, R; Fiet, J; Grise, P; Husson, JM; Kuhn, JM; Louis, JF; Moulonguet, A; Navratil, H | 1 |
| de Jong, FH; Lamberts, SW; Uitterlinden, P | 1 |
| Fiet, J; Moguilewsky, M; Raynaud, JP; Tournemine, C | 1 |
| Bélanger, A; Brun, D; Dupont, A; Gagné, C; Giguère, M; Labrie, F; Lupien, PJ; Moorjani, S | 1 |
| Cotard, M; Moguilewsky, M; Proulx, L; Raynaud, JP; Tournemine, C | 1 |
| Béland, G; Elhilali, M; Fradet, Y; Laroche, B; Ramsey, EW; Tewari, HD; Venner, PM | 1 |
| Navratil, H | 1 |
| Hubert, J; Lamy, P; Seigneur, J; Trechot, PF | 1 |
| Moguilewsky, M; Tournemine, C | 1 |
| Béland, G; Elhilali, M; Fradet, Y; Laroche, B; Ramsey, EW; Trachtenberg, J; Venner, PM | 1 |
| Bélanger, A; Dupont, A; Labrie, F | 1 |
| Bélanger, A; Cusan, L; Kelly, PA; Labrie, F; Raynaud, JP; Séguin, C | 1 |
| Belanger, A; Cusan, L; Dupont, A; Fazekas, AT; Husson, JM; Labrie, F; Lefebvre, FA; Raynaud, JP | 1 |
| Belanger, A; Cusan, L; Dupont, A; Emond, JP; Fazekas, AT; Husson, JM; Laberge, JG; Labrie, F; Lefebvre, FA; Monfette, G; Raynaud, JP | 1 |
| Belanger, A; Dupont, A; Fazekas, AT; Gareau, J; Husson, JM; Labrie, F; Lacoursiere, Y; Monfette, G; Raynaud, JP; Sandow, J | 1 |
| Faure, N; Fazekas, AT; Jean, C; Laroche, B; Lemay, A; Plante, R; Robert, G; Roy, R; Thabet, M | 1 |
| Belanger, A; Dupont, A; Labrie, F; Lefebvre, FA; Raynaud, JP | 1 |
| Bélanger, A; Dupont, A; Emond, J; Labrie, F; Monfette, G | 1 |
| Belanger, A; Cusan, L; Dupont, A; Emond, JP; Fazekas, AT; Husson, JM; Laberge, JG; Labrie, F; Lacourciere, Y; Monfette, G; Raynaud, JP | 1 |
| Doré, JC; Fiet, J; Gô, AL; Ojasoo, T; Raynaud, JP | 1 |
| Chander, S; Cheung, P; Choo, R; Danjoux, C; Deboer, G; Loblaw, A; Morton, G; Pearce, A; Szumacher, E; Woo, T | 1 |
| Brower, V | 1 |
| Cheung, P; Choo, R; Danjoux, C; Gardner, S; Loblaw, DA; Morton, G; Pearse, M; Szumacher, E | 2 |
2 review(s) available for buserelin and nilutamide
| Article | Year |
|---|---|
What is an antiandrogen and what is the physiological and pharmacological rationale for combined "castration" + "antiandrogen" therapy.
Topics: Androgen Antagonists; Animals; Buserelin; Combined Modality Therapy; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms; Rats; Receptors, Steroid | 1987 |
[New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Topics: Acid Phosphatase; Androgen Antagonists; Buserelin; Drug Synergism; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Hormones; Humans; Imidazoles; Imidazolidines; Male; Prostate; Prostatic Neoplasms | 1983 |
6 trial(s) available for buserelin and nilutamide
| Article | Year |
|---|---|
Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Drug Evaluation; Humans; Imidazoles; Imidazolidines; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Prostatic Neoplasms; Testosterone | 1989 |
Total androgen blockade vs orchiectomy in stage D2 prostate cancer.
Topics: Androgen Antagonists; Buserelin; Clinical Trials as Topic; Humans; Imidazoles; Imidazolidines; Male; Orchiectomy; Prostatic Neoplasms | 1987 |
Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Clinical Trials as Topic; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms | 1987 |
Total androgen blockade for metastatic cancer of the prostate.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Combined Modality Therapy; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Placebos; Prognosis; Prostatic Neoplasms; Random Allocation; Remission Induction | 1988 |
Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Buserelin; Double-Blind Method; Hormones; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prostatic Neoplasms | 1993 |
Efficacy of salvage radiotherapy plus 2-year androgen suppression for postradical prostatectomy patients with PSA relapse.
Topics: Aged; Androgen Antagonists; Buserelin; Drug Administration Schedule; Follow-Up Studies; Humans; Imidazolidines; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Salvage Therapy; Survival Rate; Time Factors | 2009 |
18 other study(ies) available for buserelin and nilutamide
| Article | Year |
|---|---|
Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Follow-Up Studies; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Vision, Ocular | 1991 |
Maximal androgen blockade in prostatic cancer.
Topics: Androgen Antagonists; Buserelin; Flutamide; Goserelin; Humans; Imidazoles; Imidazolidines; Leuprolide; Male; Orchiectomy; Prostatic Neoplasms | 1991 |
Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Topics: Adrenocorticotropic Hormone; Animals; Buserelin; Cyproterone; Cyproterone Acetate; Delayed-Action Preparations; Goserelin; Imidazoles; Imidazolidines; Ketoconazole; Luteinizing Hormone; Male; Orchiectomy; Organ Size; Prostate; Prostatic Neoplasms; Rats; Rats, Inbred Strains | 1988 |
Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
Topics: Androgen Antagonists; Animals; Buserelin; Diethylstilbestrol; Humans; Imidazoles; Imidazolidines; Kinetics; Male; Orchiectomy; Organ Size; Prostate; Prostatic Neoplasms; Rats; Receptors, Androgen; Receptors, Cell Surface; Receptors, LHRH; Receptors, Steroid; Testosterone | 1986 |
Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Humans; Imidazoles; Imidazolidines; Lipoproteins, HDL; Male; Prostatic Neoplasms | 1987 |
Pulmonary complications of hormone treatment in prostate carcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Pulmonary Fibrosis | 1988 |
The antiandrogen anandron potentiates the castrating effect of the LH-RH agonist buserelin in the rat.
Topics: Administration, Oral; Androgen Antagonists; Animals; Buserelin; Drug Synergism; Imidazoles; Imidazolidines; Injections, Subcutaneous; Male; Orchiectomy; Prostate; Rats; Rats, Inbred Strains; Testis; Testosterone | 1988 |
Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
Topics: Adrenocorticotropic Hormone; Aged; Androgen Antagonists; Androgens; Buserelin; Castration; Combined Modality Therapy; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Gonadotropin-Releasing Hormone; Humans; Hydrocortisone; Imidazoles; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1984 |
Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat.
Topics: Animals; Buserelin; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Imidazoles; Imidazolidines; Luteinizing Hormone; Male; Organ Size; Prostate; Rats; Receptors, Cell Surface; Receptors, LH; Seminal Vesicles; Testosterone | 1981 |
New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist.
Topics: Androgen Antagonists; Animals; Buserelin; Drug Therapy, Combination; Gonadal Steroid Hormones; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Rats; Testis | 1983 |
New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen.
Topics: Androgen Antagonists; Animals; Buserelin; Castration; Dihydrotestosterone; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Hormones; Humans; Imidazoles; Imidazolidines; Male; Prostate; Prostatic Neoplasms; Rats; Seminal Vesicles; Testosterone | 1983 |
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Hormones; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Radiography; Testosterone | 1983 |
Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Bone and Bones; Buserelin; Castration; Drug Therapy, Combination; Hormones; Humans; Imidazoles; Imidazolidines; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Radiography; Testis; Testosterone | 1983 |
Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.
Topics: Acid Phosphatase; Adenocarcinoma; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Testosterone | 1984 |
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Bone Neoplasms; Buserelin; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Rats | 1982 |
How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?
Topics: Aged; Androgen Antagonists; Anemia; Antineoplastic Agents, Hormonal; Buserelin; Clinical Trials, Phase II as Topic; Hemoglobins; Humans; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Radiotherapy, Adjuvant; Sickness Impact Profile; Testosterone | 2005 |
Watchful waiting beats androgen deprivation therapy in early prostate cancer.
Topics: Aged; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Buserelin; Drug Prescriptions; Flutamide; Humans; Imidazolidines; Leuprolide; Male; Patient Education as Topic; Patient Satisfaction; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis | 2008 |
Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and/or positive surgical margins.
Topics: Aged; Androgen Antagonists; Buserelin; Combined Modality Therapy; Humans; Imidazolidines; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Survival Rate | 2009 |